Delving into the Latest Updates on Guangzhou SIG Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Monoclonal antibody

CAR-M

CAR-NK

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5

Top 5 Drug Type	Count

Monoclonal antibody	2
CAR-M	1
CAR-NK	1
CAR-T	1

Top 5 Target	Count

Siglec(Sialic acid binding Ig like lectins)	4

1.主要研究目的：评估 SIG001 在晚期实体瘤患者中的安全性和耐受性。 2.次要研究目的：确定 SIG001 的 II 期临床研究推荐剂量（Recommended Phase II dose ，RP2D）。评估 SIG001 在晚期实体瘤患者中的药代动力学（Pharmacokinetics ，PK）特征。评估 SIG001 在晚期实体瘤患者中的药效动力学（Pharmacodynamics ，PD）特征。评估 SIG001 在晚期实体瘤患者中的初步抗肿瘤活性。评估 SIG001 在晚期实体瘤患者中的免疫原性。 3.探索性目的：探索 SIG001 的暴露量/剂量与安全性以及临床疗效之间的关系。探索潜在的生物标记物（如 SIG）的表达水平（如适用），并与药物的暴露量、疗效、安全性进行相关性分析。探索事件发生时间终点如缓解持续时间(Duration ofresponse，DoR)和无进展生存期(Progression-free survival ，PFS)。

[Translation]

1. Primary Study Objective: To evaluate the safety and tolerability of SIG001 in patients with advanced solid tumors. 2. Secondary Study Objectives: To determine the recommended Phase II dose (RP2D) of SIG001 in a Phase II clinical trial. To evaluate the pharmacokinetic (PK) characteristics of SIG001 in patients with advanced solid tumors. To evaluate the pharmacodynamic (PD) characteristics of SIG001 in patients with advanced solid tumors. To assess the preliminary antitumor activity of SIG001 in patients with advanced solid tumors. To assess the immunogenicity of SIG001 in patients with advanced solid tumors. 3. Exploratory Objective: To explore the relationship between SIG001 exposure/dose and safety and clinical efficacy. Explore the expression levels of potential biomarkers (such as SIG, if applicable) and perform correlation analyses with drug exposure, efficacy, and safety. Explore time endpoints such as duration of response (DoR) and progression-free survival (PFS).

Start Date-

Sponsor / Collaborator

Guangzhou SIG Biomedical Technology Co., Ltd.

100 Clinical Results associated with Guangzhou SIG Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou SIG Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Guangzhou SIG Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou SIG Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SIG-001 (Sigpharm) ( Siglec )	Advanced Malignant Solid Neoplasm More	Phase 1
SIG-CAR-NK (Sigpharm) ( Siglec )	Neoplasms More	Preclinical
SIG-CAR-M (Sigpharm) ( Siglec )	Neoplasms More	Preclinical
Anti-Vκ4-1-IgLC mAb (Sigpharm)	Neoplasms More	Preclinical
SIG-CAR-T (Sigpharm) ( Siglec )	Neoplasms More	Preclinical